Amgen reported robust first-quarter 2026 earnings driven by broad strength across its portfolio despite recent patent expirations affecting key products like Prolia. The company continues to invest heavily in R&D with $7.3 billion spent in 2025, maintaining a deep innovation pipeline and strong collaborations with partners such as AstraZeneca. However, pricing pressures persist due to payer consolidation, biosimilar competition, and regulatory scrutiny, including ongoing FDA challenges surrounding TAVNEOS. Amgen’s scale, biologics expertise, and strategic alliances underpin its competitive moat and growth prospects while it navigates industry-wide reimbursement reforms and global market complexities.